Matinas BioPharma Holdings, Inc. (MTNB)Healthcare | Biotechnology | Bedminster, United States | NYSE American
0.20 USD
After hours: 0.20 +0.00 (0.200%) ⇧ (Aug. 28, 2026, 7:44 p.m. EDT) |
Hot Take ↕ | Aug. 22, 2026, 5:32 a.m. EDT
The immediate outlook is severely compromised by a relentless downward price spiral. Over the last two weeks, the stock has tumbled from $0.29 to $0.20, erasing nearly half its value in just fourteen days. This crash is compounded by a catastrophic multi-year structural decline; the asset has lost 94% of its value over the past nine years, with the last three consecutive years showing negative returns. While a strategic combination with GH Power offers a potential narrative reset, the current price action suggests the market is aggressively pricing out the risks of this distressed biotech pivot. There is no dividend to provide a floor, and the fundamentals remain deeply impaired with negative earnings and cash flow. |
| Model | MAE |
|---|---|
| AutoARIMA ✓ | 0.563955 |
| AutoETS | 0.563961 |
| MSTL | 0.566379 |
| AutoTheta | 0.643121 |
Forecast horizon: 45 days | Selected: AutoARIMA
| Forecast Reliability | |
|---|---|
| Score | 23% |
| H-stat | 97.03 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.105 |
| Excess Kurtosis | -1.34 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 0.333 |
| Market Cap | 2,938,559 |
| Forward P/E | -0.07 |
| Beta | 1.75 |
| Website | https://www.matinasbiopharma.com |
| Attribute | Value |
|---|---|
| 52 Week Change | -0.89071035 |
| Address1 | 1,545 Route 206 South |
| Address2 | Suite 302 |
| All Time High | 199.5 |
| All Time Low | 0.178 |
| Ask | 0.1982 |
| Ask Size | 100 |
| Average Daily Volume10 Day | 2,057,320 |
| Average Daily Volume3 Month | 5,554,074 |
| Average Volume | 5,554,074 |
| Average Volume10Days | 2,057,320 |
| Beta | 1.747 |
| Bid | 0.1912 |
| Bid Size | 300 |
| Book Value | 0.281 |
| City | Bedminster |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 0.2 |
| Current Ratio | 0.847 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,786,665,600 |
| Day High | 0.2 |
| Day Low | 0.1931 |
| Debt To Equity | 0.333 |
| Display Name | Matinas BioPharma |
| Earnings Call Timestamp End | 1,723,667,400 |
| Earnings Call Timestamp Start | 1,723,667,400 |
| Earnings Timestamp End | 1,755,115,200 |
| Earnings Timestamp Start | 1,755,115,200 |
| Ebitda | -6,662,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -0.328 |
| Enterprise Value | 2,183,559 |
| Eps Forward | -3.0 |
| Eps Trailing Twelve Months | -1.15 |
| Esg Populated | 0 |
| Exchange | ASE |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 0.39104 |
| Fifty Day Average Change | -0.19104 |
| Fifty Day Average Change Percent | -0.48854336 |
| Fifty Two Week Change Percent | -89.07104 |
| Fifty Two Week High | 2.14 |
| Fifty Two Week High Change | -1.94 |
| Fifty Two Week High Change Percent | -0.90654206 |
| Fifty Two Week Low | 0.178 |
| Fifty Two Week Low Change | 0.022 |
| Fifty Two Week Low Change Percent | 0.123595506 |
| Fifty Two Week Range | 0.178 - 2.14 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,405,949,400,000 |
| Float Shares | 11,446,129 |
| Forward Eps | -3.0 |
| Forward P E | -0.06666667 |
| Free Cashflow | -2,448,500 |
| Full Exchange Name | NYSE American |
| Full Time Employees | 2 |
| Fullday Change | 0.0 |
| Fullday Change Percent | 0.0 |
| Fullday Price | 0.2004 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Gross Profits | 0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.23752001 |
| Held Percent Institutions | 0.022119999 |
| Implied Shares Outstanding | 14,692,796 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,725,321,600 |
| Last Split Factor | 1:50 |
| Long Business Summary | Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, identifies and develops pharmaceutical products using its lipid nanocrystal (LNC) platform technology. The company's LNC delivery technology platform utilizes lipid nanocrystals for the delivery of small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides. Its lead product candidate is MAT2203, an oral formulation of amphotericin B that is starting Phase 3 clinical trials for the treatment of aspergillosis and cryptococcosis, as well as prevention of invasive fungal infections in patients due to immunosuppressive therapy. It offers MAT2501, an orally administered formulation of amikacin. The company was incorporated in 2013 and is based in Bedminster, New Jersey. |
| Long Name | Matinas BioPharma Holdings, Inc. |
| Market | us_market |
| Market Cap | 2,938,559 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_243651290 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -7,309,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 2,938,559 |
| Open | 0.1985 |
| Operating Cashflow | -6,420,000 |
| Operating Margins | 0.0 |
| Payout Ratio | 0.0 |
| Phone | 908 484 8805 |
| Post Market Change | 0.00039999187 |
| Post Market Change Percent | 0.19999593 |
| Post Market Price | 0.2004 |
| Post Market Time | 1,787,960,658 |
| Previous Close | 0.2 |
| Price Hint | 4 |
| Price To Book | 0.71174383 |
| Profit Margins | 0.0 |
| Quick Ratio | 0.564 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | 0.0 |
| Regular Market Change Percent | 0.0 |
| Regular Market Day High | 0.2 |
| Regular Market Day Low | 0.1931 |
| Regular Market Day Range | 0.1931 - 0.2 |
| Regular Market Open | 0.1985 |
| Regular Market Previous Close | 0.2 |
| Regular Market Price | 0.2 |
| Regular Market Time | 1,787,947,200 |
| Regular Market Volume | 386,116 |
| Return On Assets | -0.56172 |
| Return On Equity | -1.41235 |
| Sand P52 Week Change | 0.1966995 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 14,692,796 |
| Shares Percent Shares Out | 0.0152 |
| Shares Short | 223,898 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 473,657 |
| Short Name | Matinas Biopharma Holdings, Inc |
| Short Percent Of Float | 0.0153 |
| Short Ratio | 0.02 |
| Source Interval | 15 |
| State | NJ |
| Symbol | MTNB |
| Total Cash | 761,000 |
| Total Cash Per Share | 0.052 |
| Total Debt | 6,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -1.15 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 0.60981 |
| Two Hundred Day Average Change | -0.40981 |
| Two Hundred Day Average Change Percent | -0.672029 |
| Type Disp | Equity |
| Volume | 386,116 |
| Website | https://www.matinasbiopharma.com |
| Zip | 7,921 |